Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy

Table 2

Univariate and multivariate binary logistic regression analyses of factors affecting clinical outcome in anti-PLA2R-positive PMN patients at 12 months (a) and 24 months (b).

(a)

	Univariate analysis				Multivariate analysis
		CI 95%				CI 95%
	HR	Lower	Higher	value	HR	Lower	Higher	value
BAFF/BLyS (>6.1 ng/mL)	0.177	0.075	0.420	<0.001	0.150	0.046	0.485	0.002
APRIL (>4.2 ng/mL)	0.291	0.131	0.646	0.002	0.331	0.130	0.842	0.020
eGFR (mL/min)	1.006	0.997	1.015	0.203	1.000	0.992	1.009	0.917
Daily proteinuria (g/day)	0.949	0.889	1.013	0.119	0.949	0.856	1.052	0.318
Anti-PLA2R (RU/mL)	0.993	0.989	0.998	0.006	1.003	0.994	1.011	0.519

(b)

	Univariate analysis				Multivariate analysis
		CI 95%				CI 95%
	HR	Lower	Higher	value	HR	Lower	Higher	value
BAFF/BLyS (>6.1 ng/mL)	0.181	0.076	0.435	<0.001	0.157	0.047	0.525	0.003
APRIL (>4.2 ng/mL)	0.256	0.110	0.594	0.001	0.328	0.125	0.855	0.023
eGFR (mL/min)	1.005	0.996	1.014	0.277	1.000	.991	1.009	0.974
Daily proteinuria (g/day)	0.941	0.879	1.007	0.079	0.940	0.846	1.044	0.250
Anti-PLA2R (RU/mL)	0.993	0.988	0.998	0.005	1.003	0.994	1.011	0.547

CI: confidence interval; HR: hazard ratio; eGFR: estimated glomerular filtration rate.